Takeda's Phase III Dengue Vaccine Results Bring Them "One Step Closer" to Stopping Tropical Disease

Dengue fever affects as many as 400 million people annually and is caused by one of four related viruses transmitted by mosquitoes. The trial showed the vaccine was efficacious in preventing dengue fever by any of the four serotypes.